RESUMEN
Obesity is a major public health problem worldwide. Only relatively few treatment options are, at present, available for the management of obese patients. Furthermore, treatment of obesity is affected by the widespread misuse of drugs and food supplements. Ephedra sinica is an old medicinal herb, commonly used in the treatment of respiratory tract diseases. Ephedra species contain several alkaloids, including pseudoephedrine, notably endowed with indirect sympathomimetic pharmacodynamic properties. The anorexigenic effect of pseudoephedrine is attributable primarily to the inhibition of neurons located in the hypothalamic paraventricular nucleus (PVN), mediating satiety stimuli. Pseudoephedrine influences lipolysis and thermogenesis through interaction with ß3 adrenergic receptors and reduces fat accumulation through down-regulation of transcription factors related to lipogenesis. However, its use is associated with adverse events that involve to a large extent the cardiovascular and the central nervous system. Adverse events of pseudoephedrine also affect the eye, the intestine, and the skin, and, of relevance, sudden cardiovascular death related to dietary supplements containing Ephedra alkaloids has also been reported. In light of the limited availability of clinical data on pseudoephedrine in obesity, along with its significantly unbalanced risk/benefit profile, as well as of the psychophysical susceptibility of obese patients, it appears reasonable to preclude the prescription of pseudoephedrine in obese patients of any order and degree.
Asunto(s)
Alcaloides , Ephedra sinica , Efedrina/efectos adversos , Humanos , Obesidad/inducido químicamente , Obesidad/tratamiento farmacológico , Seudoefedrina/uso terapéuticoRESUMEN
The analgesic effect of Ephedra Herb (EH) is believed to be derived from the anti-inflammatory action of pseudoephedrine (Pse). We recently reported that ephedrine alkaloids-free EH extract (EFE) attenuates formalin-induced pain to the same level as that achieved by EH extract (EHE), which suggests that the analgesic effect of EH may not be due to ephedrine alkaloids (EAs). To examine the contribution of EAs to the analgesic effect of EH, mice were injected with formalin to induce a biphasic pain reaction (first phase, 0-5 min; second phase, 10-45 min) at various time points after oral administration of the following test drugs: ephedrine (Eph), Pse, "authentic" EHE from Tsumura & Co. (EHE-Ts), EFE, and EHE that was used as the source of EFE (EHE-To). Biphasic pain was suppressed at 30 min after administration of Eph, EHE-Ts, and EHE-To. At 6 h after administration of EFE, EHE-To, and Pse-and at 4 to 6 h after administration of EHE-Ts-only second-phase pain was suppressed; however, the effect of Pse at 6 h was not significant. These results suggested that EHE has a biphasic analgesic effect against biphasic formalin-induced pain: in the first phase of analgesia (30 min after administration), biphasic pain is suppressed by Eph; in the second phase of analgesia (4-6 h after administration), second-phase pain is alleviated by constituents other than EAs, although Pse may partially contribute to the relief of second-phase pain.
Asunto(s)
Analgésicos/uso terapéutico , Ephedra/química , Efedrina/uso terapéutico , Dolor/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Seudoefedrina/uso terapéutico , Administración Oral , Analgésicos/aislamiento & purificación , Animales , Modelos Animales de Enfermedad , Masculino , Ratones Endogámicos , Dimensión del Dolor , Extractos Vegetales/aislamiento & purificación , Prueba de Desempeño de Rotación con Aceleración Constante , Factores de TiempoAsunto(s)
Lactancia Materna/métodos , Trastornos de la Lactancia/diagnóstico , Adulto , Extracción de Leche Materna , Cabergolina , Ergolinas/uso terapéutico , Estrógenos/uso terapéutico , Conducta Alimentaria , Femenino , Homeopatía/métodos , Humanos , Recién Nacido , Trastornos de la Lactancia/etiología , Trastornos de la Lactancia/terapia , Descongestionantes Nasales/uso terapéutico , Embarazo , Prolactina/uso terapéutico , Seudoefedrina/uso terapéutico , Índice de Severidad de la EnfermedadAsunto(s)
Resfriado Común/terapia , Tos/terapia , Hipersensibilidad/tratamiento farmacológico , Vacunas contra la Influenza/uso terapéutico , Gripe Humana/tratamiento farmacológico , Medicamentos sin Prescripción/uso terapéutico , Faringitis/terapia , Rinitis/tratamiento farmacológico , Acetaminofén/uso terapéutico , Anestésicos Locales/uso terapéutico , Cetirizina/uso terapéutico , Clorfeniramina/uso terapéutico , Dextrometorfano/uso terapéutico , Difenhidramina/uso terapéutico , Costos de los Medicamentos , Quimioterapia/economía , Urgencias Médicas , Expectorantes/uso terapéutico , Primeros Auxilios/instrumentación , Glicerol/uso terapéutico , Guaifenesina/uso terapéutico , Antagonistas de los Receptores Histamínicos/uso terapéutico , Miel , Humanos , Ibuprofeno/uso terapéutico , Loratadina/uso terapéutico , Oximetazolina/uso terapéutico , Propiofenonas/uso terapéutico , Seudoefedrina/uso terapéutico , Cloruro de Sodio/uso terapéuticoRESUMEN
1) Most colds are due to viruses and resolve spontaneously after a few days. Available drugs do not modify the course of a viral cold; 2) Some drugs used to treat colds carry a risk of serious adverse effects. This includes nasal sprays, especially vasoconstrictors such as pseudo-ephedrine and, in young children, menthol, camphor, and terpene derivatives.
Asunto(s)
Resfriado Común/terapia , Medicamentos sin Prescripción/uso terapéutico , Adulto , Alcanfor/efectos adversos , Niño , Preescolar , Contraindicaciones , Femenino , Humanos , Lactante , Recién Nacido , Mentol/efectos adversos , Descongestionantes Nasales/administración & dosificación , Descongestionantes Nasales/efectos adversos , Descongestionantes Nasales/uso terapéutico , Medicamentos sin Prescripción/administración & dosificación , Medicamentos sin Prescripción/efectos adversos , Embarazo , Seudoefedrina/administración & dosificación , Seudoefedrina/efectos adversos , Seudoefedrina/uso terapéutico , Terpenos/administración & dosificación , Terpenos/efectos adversos , Terpenos/análisis , Terpenos/uso terapéuticoRESUMEN
UNLABELLED: Antihistamines and nasal decongestants are well-established therapeutics in allergic rhinitis. However, no data are available which directly compare the effect size of the single substances with their combination in a single study including placebo (PLA) treatment. OBJECTIVE: The aim of this study was to evaluate the effect of a combination of cetirizine (CET) and pseudoephedrine (PSE) and to compare it to treatment with CET or PSE alone and to PLA during grass pollen allergen challenge in an environmental challenge chamber (ECC). MATERIAL AND METHODS: In a randomized, double-blind, placebo-controlled, four-way crossover study the effect of a combination of 10 mg CET with 120 mg PSE (CET + PSE) versus CET or PSE alone or PLA on symptoms, nasal flow, and nasal secretions was investigated in 49 patients with intermittent allergic rhinitis. Subjects underwent four 6-h pollen exposures in an ECC with administration of the drugs after 2 h. RESULTS: The induction of nasal symptoms, nasal secretion and nasal obstruction (measured as nasal flow) during the first 2 h of pollen exposure was highly reproducible at the 4 consecutive exposures. The symptom of nasal obstruction was significantly reduced after treatment with CET + PSE compared to the treatment with CET or PSE alone or PLA (p < 0.0001). Furthermore, the combination treatment significantly reduced the total nasal symptom score (TNSS) and visual analogue scale score (VAS) compared to the single treatments or PLA. Nasal flow was significantly increased after treatment with CET + PSE and PSE and nasal secretions were significantly reduced by CET + PSE and CET without significant additional improvement of the combination therapy. CONCLUSION: The combination treatment with CET and PSE is more effective than treatment with single substances in subjects with allergic rhinitis.